Repository logo
 
Publication

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018-03Journal article Open access
Simple item page
dc.contributor.authorRondy, Marc
dc.contributor.authorKissling, Esther
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorGherasim, Alin
dc.contributor.authorPebody, Richard
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorPozo, Francisco
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorMcMenamin, Jim
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-Move/I-Move Group
dc.date.accessioned2019-02-06T17:46:21Z
dc.date.available2019-02-06T17:46:21Z
dc.date.issued2018-03
dc.descriptionMembers of the I-MOVE+ working group - Portugal: B. Nunes, A. Machado, A.P. Rodrigues, V. Gómez, I. Kislaya, R. Guiomar, P. Pechirra, P. Cristóvão, I. Costa (National Health Institute Doutor Ricardo Jorge, Lisbon), A.Panarra, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal).pt_PT
dc.description.abstractBetween September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.pt_PT
dc.description.sponsorshipThe five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2018;23(9):pii=18-00086. doi: 10.2807/1560-7917.ES.2018.23.9.18-00086pt_PT
dc.identifier.doi10.2807/1560-7917.ES.2018.23.9.18-00086pt_PT
dc.identifier.issn1025-496X
dc.identifier.urihttp://hdl.handle.net/10400.18/5719
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relation.publisherversionhttp://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.9.18-00086#html_fulltextpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectInfluenza Vaccinept_PT
dc.subjectVacina Antigripalpt_PT
dc.subjectDeterminantes da Saúde e da Doençapt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectCuidados de Saúdept_PT
dc.subjectEuropept_PT
dc.subjectCase control studypt_PT
dc.subjectInfluenzapt_PT
dc.subjectInfluenza Vaccinationpt_PT
dc.subjectInfluenza Vaccine Effectivenesspt_PT
dc.subjectMulticentre Studypt_PT
dc.titleInterim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studiespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage12pt_PT
oaire.citation.issue9pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume23pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Eurosurv_IMOVE_2018.pdf
Size:
532.52 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais